Updated:
Aytu BioScience
Aytu BioScience, led by CEO Josh Disbrow, is a commercial-stage specialty pharmaceutical company trading on NASDAQ and focused on ADHD treatments.
Aytu BioScience
Aytu BioScience was founded in 2015 and is headquartered in Englewood, Colorado. CEO Josh Disbrow has led the company since its inception, steering it through acquisitions and product launches that expanded its portfolio beyond initial assets. The wealth origin of its investor base is not publicly disclosed. The firm's strategy centers on licensing, acquiring, and commercializing prescription medications for attention-deficit/hyperactivity disorder (ADHD) and related pediatric conditions. Its product lineup includes Adzenys XR-ODT (amphetamine extended-release orally disintegrating tablet) and Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablet), both ADHD treatments. Aytu also markets consumer health products through its Renue division. The geographic footprint is primarily US-focused, with no disclosed international operations. Public filings indicate revenue generation from prescription sales through specialty pharmacies and direct-to-consumer channels. Aytu BioScience operates as a publicly traded company on the NASDAQ under the ticker AYTU. Its team size, while not precisely known in public disclosures, includes commercial, regulatory, and clinical functions typical for a small-cap pharma firm. As of early 2025, the company had no announced philanthropic structures or operating businesses beyond its pharmaceutical operations. The most recent operational event of note: in Q4 2024, Aytu announced a strategic restructuring to reduce debt and focus on core ADHD products (per SEC filings, 2024). The firm's structural differentiator is its hybrid model — it functions simultaneously as a commercial-stage specialty pharmaceutical company and a publicly traded entity, not a traditional family office or private investment vehicle. This structure subjects it to full SEC reporting and shareholder scrutiny, differentiating its capital allocation from the opaque governance typical of family offices.
General information
Firm type
Asset Manager
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Englewood
Corporate office
Englewood, CO, United States
Principals
Josh Disbrow
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Aytu BioScience?
CEO Josh Disbrow leads decision-making at Aytu BioScience, as disclosed in SEC filings and company announcements. The firm operates with a management team that includes a chief financial officer and a board of directors who oversee strategic direction.
Is Aytu BioScience structured as a family office?
No. Aytu BioScience is a publicly traded specialty pharmaceutical company listed on NASDAQ (ticker: AYTU). It does not operate as a family office or asset manager for a single family.
What investment stages does Aytu BioScience typically target?
Aytu focuses on commercial-stage pharmaceutical assets, specifically licensed or acquired prescription medications that have already received FDA approval or are nearing approval. It does not typically invest in early-stage research or preclinical assets.
Which sectors does Aytu BioScience explicitly avoid?
Aytu's public disclosures do not list sectors it explicitly avoids. However, its operations are narrowly focused on central nervous system (CNS) conditions, primarily ADHD, and related pediatric health products.
How does Aytu BioScience source proprietary deal flow?
Aytu sources drug assets through licensing agreements and acquisitions from other pharmaceutical companies, as evidenced by its product portfolio. The firm does not publicly describe a proprietary sourcing model or network.
Does Aytu BioScience participate in fund commitments or only direct deals?
Aytu BioScience operates exclusively through direct asset acquisitions and licensing agreements. It does not participate in fund commitments or invest in external investment vehicles.
Where does the underlying wealth come from?
The underlying wealth of Aytu BioScience's investors is not publicly disclosed. As a publicly traded company, its shareholders include institutional and retail investors, but specific family office affiliations are not reported.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: